Chunxiao Xu
Chunxiao Xu
EMD Serono, Merck KGaA
Verified email at
Cited by
Cited by
miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and maydownregulate the high affinity cationic amino acid transporter CAT-1
J Chang, E Nicolas, D Marks, C Sander, A Lerro, MA Buendia, C Xu, ...
RNA biology 1 (2), 106-113, 2004
Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors
Y Jia, CH Yun, E Park, D Ercan, M Manuia, J Juarez, C Xu, K Rhee, ...
Nature 534 (7605), 129-132, 2016
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung CancerDDR2 Mutations in SCC of the Lung
PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ...
Cancer discovery 1 (1), 78-89, 2011
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Z Chen, K Cheng, Z Walton, Y Wang, H Ebi, T Shimamura, Y Liu, ...
Nature 483 (7391), 613-617, 2012
Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections
D Jiang, JM Weidner, M Qing, XB Pan, H Guo, C Xu, X Zhang, A Birk, ...
Journal of virology 84 (16), 8332-8341, 2010
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Y Lan, D Zhang, C Xu, KW Hance, B Marelli, J Qi, H Yu, G Qin, A Sircar, ...
Science translational medicine 10 (424), eaan5488, 2018
Loss of LKB1 and PTEN Lead to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Cancer Cell 25 (5), 590, 2014
Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus
D Jiang, H Guo, C Xu, J Chang, B Gu, L Wang, TM Block, JT Guo
Journal of virology 82 (4), 1665-1678, 2008
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase InhibitorsERK Signaling and EGFR Resistance
D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ...
Cancer discovery 2 (10), 934-947, 2012
EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors
CM Fillmore, C Xu, PT Desai, JM Berry, SP Rowbotham, YJ Lin, H Zhang, ...
Nature 520 (7546), 239-242, 2015
Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
Z Chen, T Sasaki, X Tan, J Carretero, T Shimamura, D Li, C Xu, Y Wang, ...
Cancer research 70 (23), 9827-9836, 2010
Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung CancerCombined EGFR and MEK Inhibition Prevents TKI Resistance
EM Tricker, C Xu, S Uddin, M Capelletti, D Ercan, A Ogino, CA Pratilas, ...
Cancer discovery 5 (9), 960-971, 2015
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRPIKK Inhibitor Torin2 with Antitumor Activity
Q Liu, C Xu, S Kirubakaran, X Zhang, W Hur, Y Liu, NP Kwiatkowski, ...
Cancer research 73 (8), 2574-2586, 2013
Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes
F Liu, M Campagna, Y Qi, X Zhao, F Guo, C Xu, S Li, W Li, TM Block, ...
PLoS pathogens 9 (9), e1003613, 2013
Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus
C Xu, H Guo, XB Pan, R Mao, W Yu, X Xu, L Wei, J Chang, TM Block, ...
Journal of virology 84 (18), 9332-9340, 2010
Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung CancerIdentifying Lkb1-Mutant Synthetic Lethal Targets
Y Liu, K Marks, GS Cowley, J Carretero, Q Liu, TJF Nieland, C Xu, ...
Cancer discovery 3 (8), 870-879, 2013
STING agonists induce an innate antiviral immune response against hepatitis B virus
F Guo, Y Han, X Zhao, J Wang, F Liu, C Xu, L Wei, JD Jiang, TM Block, ...
Antimicrobial agents and chemotherapy 59 (2), 1273-1281, 2015
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
L Xu, E Kikuchi, C Xu, H Ebi, D Ercan, KA Cheng, R Padera, JA Engelman, ...
Cancer research 72 (13), 3302-3311, 2012
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionHeterogeneity in Tumors and Resistance …
M Soucheray, M Capelletti, I Pulido, Y Kuang, CP Paweletz, JH Becker, ...
Cancer research 75 (20), 4372-4383, 2015
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
H Zhang, C Fillmore Brainson, S Koyama, AJ Redig, T Chen, S Li, ...
Nature communications 8 (1), 14922, 2017
The system can't perform the operation now. Try again later.
Articles 1–20